Yue-Sai suitor?
This article was originally published in The Rose Sheet
Executive Summary
Procter & Gamble may be shopping for the Coty-owned Chinese cosmetics brand, "with an announcement possibly due by mid-January," according to report by Credit Suisse First Boston. "P&G...is believed to be aiming to grow through a combination of creating new brands in China, expanding its existing brands and acquisitions," the report says. P&G currently markets a number of brands in China, including SK-II prestige cosmetics. While the company declined to comment on a potential acquisition, P&G notes it is always interested in expanding its market share in the region. Yue-Sai, the number one prestige cosmetics brand in China, was founded in 1992 by Kan Yue-Sai, who sold a controlling stake to Coty in 1996. Yue-Sai is marketed in Asia and Europe, but the brand never reached the U.S., despite earlier indications from Coty it might launch stateside by 2002 (1"The Rose Sheet" Aug. 28, 2000, In Brief)...
You may also be interested in...
L’Oréal Yue-Sai Buy Strengthens Firm’s Position In Asia
L'Oréal is furthering efforts to build its presence in the Far East with the purchase of Chinese prestige beauty brand Yue-Sai
Yue-Sai
Chinese cosmetics brand arriving in U.S. department stores within 18 to 24 months, distribution partner Coty says. In preparing for the rollout, Yue-Sai's 150 SKUs have been repackaged in red containers and will arrive at 800 department store points-of-sale in China in September. In addition, Yue-Sai Coty Blanc Whitening Line will be reintroduced in China with new white and pale gray packaging in August. Chinese personality Yue-Sai Kan entered into a joint venture agreement with Coty in 1996 to bring the top cosmetics brand to the U.S. market; the expansion is still pending. Yue-Sai beauty sales total $40 mil. to $45 mil. annually, according to industry sources
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.